GREY:ATBPF - Post by User
Post by
Actuarialon Jun 01, 2020 2:27pm
234 Views
Post# 31097564
It is good Surprise!
It is good Surprise!Well, it is a surprise because ATB is going to have another trial Phase 2/3. However, is it a good surprise or a bad one? Given the following narratives from ATB, it is obviously a good one because the result is better than ATB's expectation. In another word, if ATB had set up dose groups like 150mg, 100mg, and 75mg, it might still meet the efficacy endpoint. We all know that in the NSAIDs world, the smaller the dose the better if it still meet the efficacy target. So, what to worry about? With respect to big pharms, 200mg is good enough for partnership, 75mg will be even better!
"The 250 mg and 200 mg doses were powered for statistical significance and the 150 mg dose was powered to only observe an efficacy response."
"ATB-346 is more potent than expected; lowest effective dose still to be established"